PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Mood Disorders

Psychiatric Times. Vol. 27 No. 10
 

Couch-Pragmatism

By S. Nassir Ghaemi, MD, MPH
Dr Ghaemi is Professor of Psychiatry at Tufts University School of Medicine and Director of the Mood Disorders Program at Tufts Medical Center. | August 18, 2010
Dr Ghaemi is professor of psychiatry at Tufts University School of Medicine and director of the Mood Disorders Program at Tufts Medical Center, Boston.

If the academic career has its heroic obligations, as William James once said, these must include occasionally defending the truth, despite personal risks and without personal rancor.

It is in this spirit that I comment on the debates around DSM-5 involving Allen Frances, MD, whose views seem to elicit sympathy from many unhappy with the DSM system (the 4th edition of which Dr Frances led). In the course of some exchanges with him in writing and on blogs, it seems to me that this is his guiding idea: “Pragmatism” should be the central basis of DSM-5. Or, in his own words, “To my mind, by far the most important [diagnostic] validator is how will any decision help or harm patient care, given the foreseeable circumstances under which it will be used.”1

At one level, this is not unreasonable: there are important practical aspects to DSM. It is used not just by doctors to treat patients, but—unfortunately—by lawyers to sue doctors; by patients to diagnose themselves; by academics to teach students . . . in short, by the whole culture. Long ago, some argued that we should have 2 handbooks: one you might call the “real” DSM, which would have our best science and our most advanced knowledge and would be used for research and practice. The other you might call the “practical” DSM, which would be how we would define things so that lawyers would not bring frivolous lawsuits and students would not misunderstand, and so on. Unfortunately, our one DSM tries to be all things to everyone, and we are left with having to prioritize.

Which matters most: pragmatism or science?

Dr Frances’ answer: common sense. But one might ask, whose common sense? First and foremost, Dr Frances says, “Do no harm.” If expanding a diagnosis, for example, bipolar disorder type II, would lead to use of more harmful drugs, such as neuroleptics, then don’t expand it. If adding a new diagnosis, for example, sexual disorders, would lead to more lawsuits, then don’t add it. Now this makes some sense, especially when one thinks of curbing lawyers. This approach would be fine if there was no truth to the matter. The problem is simple and serious: this is psychiatric gerrymandering. We have one person, or a small committee of self-appointed überexperts in DSM, overseeing the rest of the world’s experts in the science of each diagnosis, nipping and tucking proposed criteria so that our diagnostic experts will be able to feel that good outweighs harm as of 1994 (for DSM-IV). Even if one accepts this approach, one problem is that the balance of good versus harm in 1994 is not the same as in 2004 or 2014.

Look how internal medicine handles it: they have plenty of lawsuits, profit-seeking pharmaceutical companies, and lots of dangerous drugs. But they don’t make their diagnostic definitions reliant primarily on “how will any decision help or harm patient care, given the foreseeable circumstances under which it will be used.” Here are 2 parallel timelines.

The first time line, lasting 56 years:

• 1892: DSM-I for internal medicine, The Principles and Practice of Medicine, by William Osler. The causes of pneumonia are unknown, the treatments ineffective, the outcome mortal; but Osler describes the many features of pneumonias in careful, honest detail.

• 1948: 56 years, and 16 editions, later, and 28 years after his death, the last version of Osler’s textbook comes out the same year as the first randomized clinical trial of any drug, streptomycin(Drug information on streptomycin) for tuberculosis pneumonia.

The second time line, lasting 58 years to date:

• 1952: DSM-I for psychiatry, an administrative document for classifying hospitalizations.

• 1968: DSM-II, a slim document of neuroses and psychoses, largely ignored by practitioners, and mostly used for insurance documentation.

• 1980: DSM-III, a doubling of diagnoses, the use of the word “disorder” to avoid saying what is disease and what is not, but the first attempt to base diagnoses on scientific research (as Osler had done).

• 1994: DSM-IV, another growth of diagnoses by about a third, with small changes based on science and many other changes based on “pragmatism.”

• 2013: DSM-5, planned.

Which timeline had the greatest practical results? Without Osler’s clinical detail and scientific rigor in diagnosis, the antibiotic revolution would not have been so easily applied to medical practice. Think about it: we have plenty of drugs in psychiatry, but we do not seem to know which patients should get them, and which should not. Some of us use them practically indiscriminately; others hardly at all—depending on our personal tastes, or the preferences of our patients. We boomerang between pharmaceutical libertinism and puritanism. Because of the “pragmatic” approach, we have been doomed, for an entire generation, to failure in biological and treatment studies. No wonder, when one realizes that DSM-IV was specifically and consciously designed to satisfy the personal views of its writers as to what is harmful, rather than to try to match up reasonably well to nature or to our knowledge of disease.

Here is a key example of this false pragmatism. An arbitrary criterion introduced into DSM-IV was not based on scientfic evidence but rather on the “pragmatic” concern that bipolar disorder (BD) should not be overdiagnosed. DSM-IV suggests that antidepressant-induced mania should not “count” as BD; instead, it should be labeled substance-induced mood disorder. Most clinicians have followed this approach as if this condition was part of the diagnosis for major depressive disorder (MDD). Reasonable scientific evidence disproves this assumption. A systematic review of the results of 109 stud-ies that included 114,521 patients found that antidepressant-induced mania was 2.6 times higher with BD than with MDD (15.3% vs 6.0%, respectively).2

Dr Frances writes: “The scientific literature is usually limited, never easy to generalize to the real world and always subject to differing interpretations.”3 If scores of studies with over 100,000 patients are still “always” subject to “differing interpretations,” then what kind of scientific data would ever be plausibly acceptable? The best-designed studies find even more of a difference: The STAR*D study has not yet even published manic switch rates in its over 3000 MDD patients treated with antidepressants because hardly anyone got manic, which means that much less than 1% of the total sample experienced antidepressant-induced mania. In contrast, studies of BD, including the Systematic Treatment Enhancement Program for Bipolar Disorder, have generally found antidepressant-related manic switch rates, at the lowest, in about 5% of patients, ranging to up to 50% of patients with some agents.4

Another example: Dr Frances apparently strongly opposes reducing the cutoff for hypomania from 4 days to 2 or 3 days. Yet there was never a single study that established 4 days as a scientifically valid criterion for hypomania; this was just the commonsense opinion of those who wrote DSM-IV. There are now 2 well-conducted studies that show that less than 4 days adequately picks out BD from MDD based on the standard diagnostic validators, both from private practice or community settings, not the ivory tower academic setting (which Dr Frances frequently presumes is the case). In one study by the late Franco Benazzi,5 246 persons with bipolar II disorder were compared with 178 persons with MDD, using the DSM-IV Structured Clinical Interview, and differences were assessed based on the 4-day definition of hypomania versus 2 to 3 days. There was no difference in diagnostic validators (such as early age at onset, depressive recurrence, atypical feature specifier, depressive mixed state and bipolar family history) for the shorter versus longer hypomania duration definitions. Four days does not pick out anything diagnostically different from 2 to 3 days.

These results have been replicated in other studies, including the longest prospective study in mood disorders, that of Dr Jules Angst, who has followed patients for over 40 years in the Zurich cohort study. Angst was the person whose research was key to the whole definition of MDD as separate from BD in DSM-III in 1980. Angst also finds that brief hypomania, defined as 1 to 3 days in duration, is no different from longer hypomania in any diagnos-tic validators (such as family history of mood disorders, age at onset of illness, suicide attempts, treatment history, legal problems, depressive phenomenology, and hypomanic symptom phenomenology).6,7

Why were Dr Angst’s data—from the exact same study by the exact same researcher—central to making the major changes for MDD in DSM-III, but unworthy of being considered at all for much smaller changes for DSM-5 now? The dichotomy between science and pragmatism is false, as long as science meets reasonable standards of quality, as in the above studies.

Let me add that if scientific studies refute these data, then I will accept them. In the absence of such studies, though, the “pragmatic” (ie, personal) opinions of self-appointed DSM überexperts should not be the final word. A critic may say these studies have problems X, Y, and Z. Fine. All studies have limitations, but this does not mean that all data are useless. Show me studies C and D to refute A and B. Otherwise, studies A and B will be the best evidence we have, and no one’s personal opinions should be seen as more correct than those data. Certainly, sometimes data are too limited and studies too flawed, in which case opinion rules; but Frances takes this approach even in cases where good studies and legitimate data exist. (A 40-year prospective cohort study is as good as any nosological study supporting practically any DSM-IV diagnosis.) This attitude, if perpetuated from DSM-IV to DSM-5, would only ensure that our diagnostic system will continue to reflect the opinions of its writers and be a consciously artificial system, dooming all biological and treatment research, and ensuring that we will never improve our diagnoses based on scientific research.

The idea of pragmatism has an honorable genealogy. Invented by the 19th century philosopher and mathematician Charles Sanders Peirce, pragmatism meant that we should judge the truth or falsity of our ideas not by some inherent quality but by their results in experience; a theory is tested in an experiment and the results of the experiment verify or falsify the theory. This is what Peirce—and later philosophers William James and John Dewey—meant by pragmatism. They did not set up pragmatism as an alternative to science. They did not say our “pragmatic” opinions should outweigh science. They all believed science has the highest priority, and they said so, knowing fully that science has its limits, that it can often be wrong—more: that it is always wrong to some extent. And that it can be misused, as in some of the pharmaceutically related research. And that researchers have their pet ideas and blind spots (but so do nonresearchers). The beauty of science is that error is built into the process: in science, truth is corrected error, in Peirce’s phrase. Scientific work has no fear of being wrong, as long as one seeks to tell the truth as clearly and honestly as possible.

The couch-pragmatic approach—one that does not deign to conduct research, much less value it—involves a disregard for what is true, even when the research evidence provides reasonable evidence for what is true, at the expense of what we happen to think is useful. This is pure utilitarianism, not pragmatism—a bland disregard for truth. Dr Frances makes an exaggerated general premise—that science is always dubious—and applies it where he wants: BD is a favored target, but he rarely writes about decreasing the diagnostic range of MDD, a diagnosis he greatly broadened in DSM-IV. Why? Apparently because he thinks antipsychotics do more harm than antidepressants, on a “pragmatic” level. But this gerrymandering based on which drugs we like or don’t like is no way to develop a diagnostic system that actually gets us closer to understanding and effectively treating diseases. (Unless one thinks there are no diseases in psychiatry, which is a larger topic worth separate analysis.)

I have my own criticisms of DSM-5 (such as the idea of “temper dysregulation disorder,” which ignores much relevant scientific data against it and which is being pushed, pragmatically, as a way to avoid diagnosing BD in children). But I will base my critiques on scientific merits first, pragmatic aspects second—not the other way around. Why Dr Frances criticizes DSM-5—his method—is the problem, not the act of criticism. His method is to summarize perception of harm from treatments; this approach will leave us stuck in a dead end, where each revision of DSM is mere opinion, and no evolution ever occurs, as in internal medicine, toward real knowledge of disease, and real cure.

Psychiatry sits in the same place scientifically as internal medicine did at the end of the 19th century. If we are to experience the advances that internal medicine achieved, we would do well to study and follow the example of historical success. We should work vigorously to describe our psychiatric syndromes to the best of our current scientific ability, much as Osler did for medicine in his textbook. If that work is done objectively and honestly, then such definitions will promote and link to future advances in neuroscience and treatment, unlike our past “pragmatic” diagnoses. This approach to medicine is exactly what Hippocrates supported against the “pragmatic” doctors who preceded him (in the school of Cnidus, against which Hippocrates set up his school of Cos).

First do no harm? Of course, but how do you get there? The humblest and most practical approach is the hard work of science, with an honest respect for its results. This is what Hippocrates taught,8 an emphasis on knowing disease, and treating those diseases one could treat, not an abstract caution about treatment, and certainly not the postmodernist view that all criteria are arbitrary, so let’s set them up based on our personal beliefs about what produces the best outcomes in 1994 or 2013. We need to follow what Hippocrates taught, not co-opt the outcome of his philosophy while ignoring his method about how to get to that outcome; otherwise, what emerges is merely an empty slogan.

In sum, contrary to the historical meaning of Hippocratic teachings and the philosophical meaning of pragmatism, we have here a couch-pragmatism, where, from a recumbent posture, one can ignore research studies because scientific data are always dubious, but one’s own “pragmatic” opinions are self-evident.

Dr Frances' Response: Dr Ghaemi's arguments have been made--and I think effectively refuted--in several previous postings in different venues. Rather than repeat myself, please see the Bulletin of the Association for Advancement of Philosophy and Psychiatry.

Note: Information on the Bulletin can be found at Dr Phillips' article online at Psychiatric Times.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by C Mears | August 20, 2010 11:19 AM EDT

I very much appreciate Dr. Ghaemi's incisive but constructive critique of Dr. Frances's "consequentialist"approach to psychiatric diagnosis. I agree that we should not "gerrymander"our diagnostic categories in order to avert anticipated problems with poor medical practice, Big Pharma marketing, etc. Those issues should be addressed via intensive education of practitioners, once we have provided them with the best-supported, scientifically-based criteria we can devise. Of course, on some level, general medicine--like general ethics--always involves a tension between "deontological" values (based on duty or inherent "rightness") and "consequential" values (based on actual outcome and effect). For example, if we knew for a fact that criteria set "A" leads to increased morbidity and mortality when compared with criteria set "B", we might have reason to prefer criteria set "B", all other things being equal. But this is not the case with most of the diagnostic categories in dispute. For example, changing the hypomania criteria from 4 to 2 days may very well reduce morbidity and mortality by reducing suicide rates in bipolar disorder--an effect clearly associated with lithium treatment.

In fairness to my friend Allen Frances, he has (per personal communications) supported some "tightening up" changes to the diagnosis of Major Depressive Disorder with which I agree; e.g., requiring a longer duration of symptoms before making the diagnosis. Dr. Sid Zisook and I have proposed that we can reduce false positives in MDD by increasing the minimum duration of symptoms from 2 weeks to 4 weeks, in most cases. (Exceptions would include MDD with melancholia or cases presenting with suicidal ideation, which would retain the 2 week threshold). On the other hand, Dr. Zisook and I have persistently disagreed with Dr. Frances on the matter of eliminating the bereavement exclusion for MDD, for precisely the reasons Dr. Ghaemi insists upon: we believe that the best available science does not support the bereavement exclusion, and we do not believe our MDD criteria should disregard the data, based on fears of "over-prescribing" antidepressants or "medicalizing grief". [see http://www.psychiatrictimes.com/display/article/10168/1523978]

In short: absent clear and convincing empirical evidence of harm associated with a given change in diagnostic criteria, we need to go where the best science leads us. --Ron Pies





References

1. Frances A. Should practical consequences influence DSM5 decisions? Psychology Today. http://www.psychologytoday.com/blog/dsm5-in-distress/201004/should-practical-consequences-influence-dsm5-decisions. Accessed August 18, 2010.
2. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121:404-414.
3. Frances A. DSM 5 goes too far in creating new mental disorders. Psychology Today. http://www.psychologytoday.com/blog/dsm5-in-distress/201003/dsm-5-goes-too-far-in-creating-new-mental-disorders. Accessed August 18, 2010.
4. Goodwin FK, Jamison KR. Manic-Depressive Illness. 2nd ed. New York: Oxford University Press; 2007.
5. Benazzi F, Akiskal H. The duration of hypomania in bipolar-II disorder in private practice: methodology and validation. J Affect Disord. 2006;96:189-196.
6. Wicki W, Angst J. The Zurich Study. X. Hypomania in a 28- to 30-year-old cohort. Eur Arch Psychiatry Clin Neurosci. 1991;240:339-348.
7. Angst J, Gamma A, Benazzi F, et al. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73:133-146.
8. Jouanna J. Hippocrates. Baltimore: Johns Hopkins University Press; 1998.
Dr Frances responds: Dr Ghaemi’s arguments have been made—and I think effectively refuted—in several previous postings in different venues. Rather than repeat myself, please see the Bulletin of the Association for Advancement of Philosophy and Psychiatry at http://alien.dowling.edu/~cperring/aapp/bulletin.htm


 
RELATED TOPICS
Bipolar I disorder
Bipolar II disorder
Mania
Mood disorders
Psychotic affective disorders


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Journey of the Traumatized Hero: Kerouac’s On the Road and Gandhi’s Railroad Ride
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
  • Benefits of CAM Therapies for Dementia
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
CME
Advances in Psychiatric Medicine: Differential Diagnosis of Bipolar Disorder Subtypes: Indications for Adjunctive Therapies
Distinguishing Features of Borderline Personality Disorder and Bipolar Disorder—Clinical Diagnosis and Treatment
The State of the Evidence on Pediatric Bipolar Disorder


 
SEARCH MEDICA

Find peer-reviewed literature and websites for practicing medical professionals

CME on Mood Disorders
Evidence on Mood Disorders
Guidelines on Mood Disorders
Patient Education on Mood Disorders
Clinical Trials on Mood Disorders
Practical Articles on Mood Disorders
Research and Reviews on Mood Disorders
All "Mood Disorders" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy